Abstract
Background Urgent Suspected Cancer (Two Week Wait, 2WW) referrals have improved early cancer detection but are increasingly a major burden on NHS services. This has been exacerbated by the COVID-19 pandemic.
Method We developed and validated tests to assess the risk of any cancer for 2WW patients. The tests use routine blood measurements (FBC, U&E, LFTs, tumour markers), combining them using machine learning and statistical modelling. Algorithms were developed and validated for nine 2WW pathways using retrospective data from 371,799 referrals to Leeds Teaching Hospitals Trust (development set 224,669 referrals, validation set 147,130 referrals). A minimum set of blood measurements were required for inclusion, and missing data were modelled internally by the algorithms.
Results We present results for two clinical use-cases. In use-case 1, the algorithms identify 20% of patients who do not have cancer and may not need an urgent 2WW referral. In use-case 2, they identify 90% of cancer cases with a high probability of cancer that could be prioritised for review.
Conclusions Combining a panel of widely available blood markers produces effective blood tests for cancer for NHS 2WW patients. The tests are affordable, can be deployed rapidly to any NHS pathology laboratory with no additional hardware requirements.
Competing Interest Statement
RS, KL, MN, JS, NPS, GT are employed by and are shareholders in PinPoint Data Science Ltd. MM has been employed as a consultant to PinPoint Data Science Ltd in October to November 2020. Both the University of Leeds and Leeds Teaching Hospitals Trust have a royalty agreement with PinPoint Data Science Ltd, meaning that those institutions are likely to benefit financially in the event of PinPoint being commercially successful.
Funding Statement
Aspects of this work have been supported by awards from MRC Proximity to Discovery, Local Enterprise Partnership, and Innovate UK. Richard Neal, Bethany Shinkins, Geoff Hall and Michael Messenger are funded by the NIHR Leeds In Vitro Diagnostic Co-operative. PinPoint Data Science Ltd funded the data science work and time contributions of Richard Savage, Matt Neal, Kat Lloyd, Jim Skinner, Giles Tully, Nigel Sansom, and Rosie Ferguson. This research is linked to the CanTest Collaborative, which is funded by Cancer Research UK [C8640/A23385], of which RDN is an Associate Director, MM was a member of Senior Faculty, and BS was part-funded
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data for the analysis are retrospective and fully de-identified before being released to the study team. The work was carried out under service evaluation with the formal approval of the Leeds Teaching Hospitals Trust R&I and Data Governance Committee, and with the specific approval of the Trust Caldicott Guardian.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
The data will not be made available to others, as it is de-identified NHS patient data.
